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Available online 27 April 2016AbstractObjectives: Osteoporosis is a rapidly rising cause of concern for elderly patients. Various classes of drugs are available in the market.
Bisphosphonates are considered as a first-line therapy for the prevention and treatment. Denosumab is an antiresorptive agent which is a RANK
ligand inhibitor. There is a scarcity of comparison between these two classes of drugs. The aim of this study is to compare efficacy of
Bisphosphonates and Denosumab in various parameters.
Methods: Literature search was done for randomized controlled trials (RCTs) comparing bisphosphonates with denosumab. RCTs with a
treatment period of at least one year with a baseline bone mineral density (BMD) and bone turnover markers (BTM) and follow up values at one
year were included in the study. All included studies were also analysed for complications. The study has also been registered in PROSPERO
International prospective register of systematic reviews.
Results: A total of five RCTs were identified providing data on 3751 participants. In all five studies, the BMD changes at both hip and spine were
statistically significant in favour of denosumab. Result was similar in three studies that studied BMD changes at the wrist. Denosumab also
produced significant reduction in BTM as early as one month, but at one year there was no difference compared to the bisphosphonates. There
was no statistically significant differences in the complication rates.
Conclusions: Though both bisphosphonates and denosumab were effective with similar side effects, the latter was statistically superior in
increasing the BMD and reducing the BTM.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Postmenopausal osteoporosis is a disease with features of
reduction in the mass of bone, and microscopic changes in the
architecture that results in impaired strength of the bone [1].
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to an overall reduction of bone mass. This in turn increases
skeletal fragility and risk of developing fractures [2]. There-
fore the objective of treatment is to increase bone mass by
altering the balance of bone remodelling. Most currently
available drugs used to treat osteoporosis such as calcitonin,
raloxifene and bisphosphonates, acts as inhibitors to bone
resorption.
The two main properties of bisphosphonates resulting in
their efficacy are the ability to strongly bind to bone mineral
and the inhibition of mature osteoclasts [3]. Once the
bisphosphonate is strongly attached to bone, this results inlsevier B.V. This is an open access article under the CC BY-NC-ND license
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bisphosphonates act at the sites of bone resorption by entering
and inhibiting the mature osteoclastic cells.
Receptor activator of nuclear factor kappa-B ligand
(RANKL), a cytokine secreted by bone marrow stromal cells,
osteoblasts and T cells, is essential to induce osteoclast dif-
ferentiation [4]. In post-menopausal osteoporosis with estro-
gen deprivation there is raised expression and production of
RANKL, resulting in increased osteoclast activation and
increased bone resorption. Reducing the number of osteoclasts
by decreasing differentiation of precursor cells is one of the
treatment modalities of hyper-resorptive bone diseases.
Denosumab is one such fully human monoclonal antibody that
can bind and inhibit RANKL.
There are numerous studies on the efficacy of bisphospho-
nates and other medications available for osteoporosis including
denosumab. But there are very few randomised controlled trials
(RCT) directly comparing bisphosphonates and denosumab.
The aim of this systematic review was to identify studies that
simultaneously compared bisphosphonates and denosumab and
to analyse the efficacy in various parameters.
2. Materials and methods
Search Strategy: A search was done in several databases
such as Pubmed Central, Cochrane CENTRAL and MED-
LINE. The search was restricted to articles in English lan-
guage. The search terms used were osteoporosis, post-
menopausal, denosumab, bisphosphonates, bone mineral
density and C-telopeptide. A filter for RCTs was also used.
The Cochrane handbook of systematic reviews of in-
terventions was referred to identify any discrepancies and
biases in randomization, allocation concealment, blinding and
missing data in the included RCTs [5].
Inclusion criteria: All RCTs directly comparing
bisphosphonates with denosumab in post-menopausal osteo-
porosis were included. Only fully published reports with initial
and final bone mineral density (BMD) and bone turnover
markers (BTM) were included. CONSORT check list was used
to critically appraise the included studies and all the studies
fulfilled the criteria.Table 1
Characteristics of included studies.
Study Study design Drugs
Lewiecki EM et al. J Bone Miner Res. 2007 [7] Randomized Denosum
Double blind Alendron
Brown JP et al. J Bone Miner Res. 2009 [8] Randomized Denosum
Double blind Alendron
Nakamura T et al. J Clin Endocrinol Metab. 2014 [9] Randomized Denosum
Double blind Alendron
Roux C et al. Bone. 2014 [10] Randomized Denosum
Open label Risedrona
Recknor C et al. Obstet Gynecol. 2013 [11] Randomized Denosum
Open label IbandronaStatistical analysis: Data extracted included study design,
selection criteria, population demographics, type of interven-
tion, initial and final BMD, initial and final BTM as well as
complications if any. Results of all the included studies were
described in a table format. Key outcomes were percentage
changes in BMD, BTM and complications.
3. Results
A total of six RCTs were identified. In one study, the
participants had used denosumab for a long period and then
stopped before restarting the therapy [6]. This RCT was
excluded from the current study. A total of five RCTs were
identified with a total of 3751 participants. The characteristics
of the included studies are summarized in Table 1. Three
studies compared denosumab with alendronate [7e9] and one
study each for denosumab vs. risedronate [10] and denosumab
vs. ibandronate [11]. All studies were checked to identify any
discrepancies and biases in randomization, allocation
concealment and blinding based on CONSORT checklist. No
possible bias was found.
In one included RCT, subjects received variable doses of
denosumab, viz. 6, 14 or 30 mgs subcutaneously (s/c) every
three months or 14, 60, 100 or 210 mgs s/c every six months
[7]. In all the other studies, subjects received denosumab in a
dose of 60 mg s/c every six months.3.1. Bone mineral densityBaseline BMD in each of the study was noted for both the
groups of subjects. All the five included studies recorded BMD
changes at the lumbar spine and hip. In addition to this, four of
the studies recorded BMD changes at the femoral neck and three
studies at the distal radius. All the five studies reported
improvement in BMDat the lumbar spine and hip after treatment
in both groups but the improvement was statistically significant
in favour of denosumab. Four studies reported statistically
significant improvement inBMDat the femoral neck in favour of
denosumab. Three studies also reported statistically significant
improvement in BMD at the distal radius, again in favour of
denosumab. The results are shown in Table 2.Dosing Number
of patients
Age of patients
in years (SD)
Treatment
duration
(Mo)
ab Varying doses s/c every 3
or 6 months
319 62.3 (8.0) 24
ate 70 mgs orally per week 47 62.8 (8.2)
ab 60 mgs s/c every 6 months 594 64.1 (8.6) 12
ate 70 mgs orally per week 595 64.6 (8.3)
ab 60 mgs s/c every 6 months 414 69.9 (7.4) 24
ate 35 mgs orally per week 204 70.2 (7.3)
ab 60 mgs s/c every 6 months 422 67.8 (7.0) 12
te 150 mgs orally per month 402 67.7 (6.8)
ab 60 mgs s/c every 6 months 398 67.2 (8.1) 12
te 150 mgs orally per month 356 66.2 (7.8)
Table 2
Bone mineral density baseline values and changes following treatment.
Study Drugs Baseline BMD
lumbar spine
Change in BMD
lumbar spine
Baseline
BMD hip
Change in
BMD hip
Baseline BMD
femoral neck
Change in BMD
femoral neck
Change in BMD
distal radius
Lewiecki EM et al. J Bone
Miner Res. 2007 [7]
Denosumab 2.0a 8.9% e 4.8% e e 1.2%
Alendronate 2.0a 6%
p < 0.001
e 3%
p < 0.001
e e 1%
p < 0.001
Brown JP et al. J Bone Miner
Res. 2009 [8]
Denosumab 2.57 ± 0.75b 5.3% 1.75 ± 0.79b 3.5% e 2.4% 1.1%
Alendronate 2.57 ± 0.75b 4.2%
p < 0.0001
1.69 ± 0.81b 2.6%
p < 0.0001
e 1.8%
p < 0.0001
0.6%
p < 0.0001
Nakamura T et al. J Clin
Endocrinol Metab. 2014
[9]
Denosumab 2.78 ± 0.89b 9.1% 2.01 þ 0.79b 4.6% 2.38 þ 0.70b 4% 0.5%
Alendronate 2.69 ± 0.94b 7.5%
p < 0.05
1.96 þ 0.79b 3.6%
p < 0.05
2.29 þ 0.71b 2.9%
p < 0.05
-0.2%
p < 0.05
Roux C et al. Bone. 2014 [10] Denosumab 2.2 ± 1.2b 3.4% 1.6 ± 0.9b 2% 1.9 ± 0.8b 1.4% e
Risedronate 2.3 ± 1.1b 1.1%
p < 0.001
1.6 ± 0.8b 0.4%
p < 0.001
1.9 ± 0.7b 0%
p < 0.001
e
Recknor C et al. Obstet
Gynecol. 2013 [11]
Denosumab 2.5 ± 0.9b 4.1% 1.8 þ 0.7b 2.3% 2.1 þ 0.7b 1.7% e
Ibandronate 2.5 ± 0.8b 2%
p < 0.001
1.8 þ 0.7b 1.1%
p < 0.001
2.1 þ 0.7b 0.7%
p < 0.001
e
BMD, bone mineral density.
a Mean values.
b Mean ± standard deviation.
79B. Benjamin et al. / Osteoporosis and Sarcopenia 2 (2016) 77e813.2. Bone turnover markersFour of the included trials have reported baseline values of
the BTM (C-telopeptide), and the percentage in reduction at
one month and six months after initiation of treatment [8e11].
All four trials have found denosumab statistically superior to
bisphosphonates at one month and three studies have shown a
similar superiority at six months. The results are shown in
Table 3. However one trial [9] reported that at six months of
treatment there was no difference between the two groups and
another trial [8] reported that at 12 months of treatment there
was no difference between the two groups (p ¼ 0.52).3.3. ComplicationsThe various reported complications include arthralgia,
upper respiratory tract infections, nasopharyngitis, clinical
fractures and osteoporotic fractures. However there was no
statistical difference between the two groups. The results are
summarized in Table 4.
One study [7], reported the incidence of dyspepsia
(denosumab: 10.5% vs. alendronate: 26.1%) and nauseaTable 3
Bone turnover markers baseline values and changes following treatment.
Study Drugs Baselin
C-telop
(ng/mL
Brown JP et al. J Bone Miner Res. 2009 [8] Denosumab 0.705
Alendronate 0.654
Nakamura T et al. J Clin Endocrinol Metab. 2014 [9] Denosumab 0.64
Alendronate 0.61
Roux C et al. Bone. 2014 [10] Denosumab 0.52
Risedronate 0.53
Recknor C et al. Obstet Gynecol. 2013 [11] Denosumab 0.4
Ibandronate 0.4(denosumab: 11.1% vs. alendronate: 21.7%). Though these
gastrointestinal side effects were more in the alendronate
group, they were not statistically significant. One study [8]
described pyelonephritis (denosumab: 0.2% vs. alendronate:
0%) and another study [11] described the incidence of urinary
tract infection (denosumab: 3.4% vs. ibandronate: 4.6%).
Again, there was no statistical significance between the
groups. Overall fracture rates and occurrence of osteoporotic
fractures have been described in four studies with no statistical
significance between the groups. One study found no com-
plications in fracture healing in both the groups [9].
There was also no statistical significance between the
dropout rates because of adverse events, in three of the
included studies [7e9].
4. Discussion
RANK receptors are present on osteoclasts and their pre-
cursor cells. Denosumab prevents the interaction of RANKL
with these receptors. This results in blocking the formation,
functional ability, and survival of osteoclastic cells [4]. On the
other hand, bisphosphonates bind to the calciume
eptide
)
Reduction in
C-telopeptide
at 1 month
Statistical
Significance
Reduction in
C-telopeptide
at 6 months
Statistical
Significance
89% Significant 77% Significant
61% p < 0.0001 73% p < 0.0001
70.9% Significant 67 Not significant
43% p < 0.05 66.3%
77.7% Significant 60.6% Significant
17% p < 0.0001 22.5% p < 0.0001
81.1% Significant 60.5% Significant
35% p < 0.001 45.4% p < 0.001
Table 4
Common complications described in most studies.
Study Lewiecki EM et al.
J Bone Miner Res.
2007 [7]
Brown JP et al. J
Bone Miner Res.
2009 [8]
Nakamura T et al. J
Clin Endocrinol
Metab. 2014 [9]
Roux C et al.
Bone. 2014 [10]
Recknor C et al.
Obstet Gynecol.
2013 [11]
Medication used D BP D BP D BP D BP D BP
Arthralgia 19.1% 23.9% 12.6% 9.6% e e 4% 4.4% 6.1% 5.6%
URTI 24.2% 23.9% 6.1% 4.4% e e 5.1% 2.2%
Nasopharyngitis e e e e 44.4% 38.4% 3.5% 4.2%
All clinical fractures 6.7% 4.3% 4% 3.2% e e 4.4% 3.5% 3.6% 3.2%
Osteoporotic fractures 3.8% 4.3% 3% 2.2% e e 2.5% 1.4% 1.5% 1.1%
Discontinue at 1 year due to AE 1.6% 0% 0.5% 0.7% 1.1% 0.8% e e e e
D, Denosumab; BP, Bisphosphonates; URTI, Upper Respiratory Tract Infection; AE, Adverse effects.
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affecting the function and survival of osteoclasts. But they do
not affect the formation of osteoclasts [3].
For the diagnosis of osteoporosis, analysis of bone mineral
density using dual-energy X-ray absorptiometry (DXA) is the
gold standard [12]. All the included studies in this review
showed increase in BMD at lumbar spine, hip, femoral neck
and distal radius in favour of denosumab as shown in Table 2.
BMD is a commonly used marker to assess efficacy of
treatment of osteoporosis. However it is not useful to repeat the
BMD within an interval of 2 years because the effect of treat-
ment is relatively small compared to the precision of the test.
There is also no precise and consistent relationship between a
given increase in BMD and a specific decrease in fracture risk
with osteoporosis therapy. BTMs are a non-invasive way of
assessing the efficacy of the treatment. Biochemical analysis
can be used to monitor bone metabolism. Enzymes and proteins
are released during bone formation and bone resorption results
in release of products of degradation. Analysing these
biochemical markers can result in a specific and sensitive
assessment of the rate of bone formation and bone resorption.
These are C-terminal telopeptide of type 1 collagen (CTX) for
bone resorption, and procollagen type 1 N propeptide (P1NP)
for bone formation [13]. These markers usually fall by around
40% within 3 months of commencing bisphosphonate therapy.
This is also usually followed by a reduction in the levels of bone
formation markers during the next 6e12 months [14]. If the
BTM levels do not reduce after antiresorptive therapy, it could
be a result of the patient not complying with therapy, failure of
absorption or an undetected cause of secondary osteoporosis.
Denosumab has been shown to produce a very rapid fall and
suppression of resorption markers, with a slower fall in for-
mation markers [15]. Our study confirmed this finding with all
the included studies showing a very rapid fall in resorption
markers.
Denosumab has been shown to be associated with a sig-
nificant reduction in the risk of vertebral, hip, and nonvertebral
fractures compared to placebos in postmenopausal women
with osteoporosis [16]. All the included studies in this review
found no statistical significance between the groups. However,
the limitation of this study was that none of the included
studies were powered to compare fracture rates between the
groups. Previous studies in postmenopausal women havereported a greater incidence in serious adverse events of
infection for denosumab compared with placebo [6,17]. This
current study did not observe any statistical significance be-
tween the groups.
In conclusion, increasing BMD by decreasing bone
resorption through the inhibition of RANKL is an alternative
approach to the treatment of osteoporosis. Denosumab is a
human monoclonal antibody that can achieve this result. Use
of Denosumab results in significant increase in BMD and
reduction in the BTMs compared to various bisphosphonates.
There was also no statistically significant complications.
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